Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma-Reference-Cited by-同舟云学术

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

Published:2011-02-25 Issue:6 Volume:25 Page:906-908
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Short K Detweiler,Rajkumar S V,Larson D,Buadi F,Hayman S,Dispenzieri A,Gertz M,Kumar S,Mikhael J,Roy V,Kyle R A,Lacy M Q

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201129.pdf

Reference6 articles.

1. Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962–2972.

2. Madan S, Kumar S . Review: extramedullary disease in multiple myeloma. Clin Adv Hematol Oncol 2009; 7: 802–804.

3. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M . Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2009; 21: 325–330.

4. Kyle RA, Gertz MA, Witzig TE, Lust J, Lacy M, Dispenzieri A et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003; 78: 21–33.

5. Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas [see comment]. Br J Haematol 2001; 113: 422–424.

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

2. Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐BCMA CAR T‐cell‐based therapy;American Journal of Hematology;2024-08-28

3. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

4. Clinical outcomes and microenvironment profiling of relapsed/refractory extramedullary disease of multiple myeloma patients with anti-BCMA CAR T cell-based therapy;2024-04-19

5. Advances in the Treatment of Extramedullary Multiple Myeloma;Journal of Clinical Personalized Medicine;2024